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Abstract
Background: Beta Thalassaemia Major (βTM) is a chronic genetic illness whereby the challenges faced by patients
exposes them to increased risk of psychosocial issues. Despite this, a disease-specific tool to measure the impact of
this illness on adult patients has yet to be developed.
Methods: In collaboration with βTM adult patients, this study aimed to develop a comprehensive, disease-specific, easy to
use psychometrically sound tool to measure the impact of chelation and transfusion dependent βTM in a cross-cultural
patient group in England.The Thalassaemia Life Index (ThALI) was developed in two stages – item generation and pre-testing
and item reduction – in collaboration with service users. Recruited adult patients shaped the design of the instrument
including its statements and subscales. Standard item reduction techniques were used to develop the instrument.
Results: The final version of the ThALI encompasses 35 statements and five sub-scales - general physical health, coping, body
image, appearance and confidence, social relationships and autonomy. This endorses the multidimensionality of quality of life
(QoL). The factor structure of the ThALI is highly stable and its internal consistency is high (alpha = 0.87 for the overall scale;
0.83–0.94 for its subscales). The ThALI has sound scaling assumptions, acceptability and score variability. Content validity was
confirmed by experts and service user interviewees. The loadings for the items retained were adequate and the item
discriminant validity sound.
Conclusions: The ThALI covers the impact of βTM in adult patients. Preliminary testing shows its multidimensionality to be
reliable and valid. The national authentication of the tool with patients treated in Centres of Excellence will aim to provide
further evidence regarding the ThALI’s psychometric properties. Once authenticated, the ThALI may be utilised in research
and in clinical settings to assess the effects of new therapies and/or interventions from the patients’ perspective to inform
practice and/or to identify areas of concern.
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Introduction
Beta thalassaemia major (βTM) is a genetic red-cell
blood disorder that causes the body to manufacture an
abnormal form of haemoglobin which is the protein
molecule in red blood cells that carries oxygen from the
lungs to the rest of the body. Consequently, red blood
cells are destroyed, and severe anaemia develops. The
prevalence of βTM is commonplace in people with
Mediterranean, Middle Eastern, South Asian, South East
Asian and the Far Eastern backgrounds [1]. Globally in
2015, it resulted in 16,800 deaths [2].
Clinical symptoms are broad and variable in severity,
usually starting at around six months of age and include
growth problems (weak and fragile bones), anaemia
(leading to tiredness, weakness and shortness of breath,
jaundice), a swollen abdomen caused by an enlarged
liver or spleen, and reduced fertility. Treatment for this
chronic illness involves regular blood transfusions and
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chelation therapy. Chelation therapy can be in the form
of a subcutaneous infusion which is given via a small
pump-like device given up to seven nights per week over
8-12 hours. Alternatively, the chelation treatment can be
given in tablet form or a combination of a tablet and the
infusion pump [3].
The above stated treatment options have improved the
prognosis for patients, but long-term survival remains a
challenge. About half of the patients being treated in the UK
die before the age of 35 years from failure to adhere to this
arduous treatment [4]. Links exist between the burdensome
treatment of βTM and increased psychosocial problems [5]
which in turn can lead to poor adherence and in some cases
death [6]. There is no cure for this chronic, lifelong disease.
Conventionally, objective considerations like changes in
health parameters, disease status and costs of care are used
to describe disease activity and treatment efficacy in the clin-
ical management and research of βTM patients [7], however,
it has become increasingly clear that the perspective of the
patient is also a useful and significantly important variable
[7]. Metrics underpin clinical research and practice and pa-
tient involvement in the content and design of such tools
ensures their clinical relevance. It is becoming increasingly
customary to evaluate medical/health-related outcomes
from the perspective of the patient [8], however, frequently
they are not involved in the design and development of in-
struments even though there is much to learn from them.
Several rigorously developed and psychometrically
sound instruments are available for use, but they evaluate
the need for psychosocial support and measure the psy-
chosocial effects of new treatments [9] or assess satisfac-
tion and adherence [10]. Such tools are not designed for
measuring quality of life (QoL) in βTM adult patients.
More specifically, they have not been developed for
English-speaking adults (from different origins) diagnosed
with chelation and transfusion dependent βTM only [10–
12]. Generic standardised and validated QoL question-
naires do exist, like the Medical Outcomes Study Short
Form 36 [13] and The WHOQoL-100 [14], however, gen-
eric instruments in general do not cover areas of outcome
that are highly relevant in specific diseases and are not
specific to a disease type [15]. They also have limited re-
sponsiveness and/or fail to detect change [16].
In collaboration with βTM adult patients, the aim of
this project was to develop a disease-specific instrument
to measure the impact of chelation and transfusion
dependent βTM in a cross-cultural patient group in
England. This article describes the study methodology
which includes the involvement and views of patients.
Methods
Study setting and participants
In this article, the terms ‘patients’ and ‘service users’ will
be used interchangeably. The adult patients involved in
this collaboration are National Health Service (NHS)
service users.
The study was conducted in collaboration with the pa-
tients (adult) recruited. Patient involvement/input was
significantly important and ‘carried weight’. The number
of service users involved, and the level of their involve-
ment differed at each stage of the project. At both stages
of the ThALI’s development, patients were involved in
structured activities which will be become apparent as
the activity is described in each stage of the development
of the ThALI. The study participants encompassed a
purposive community and clinical (small) sample of che-
lation and transfusion dependent adult βTM patients.
Stage 1 of 2: item generation and pre-testing
The ThALI was developed in accordance with psycho-
metric theory [17] in two stages in collaboration with
patients.
Item generation
In this stage, a preliminary questionnaire and its state-
ments were generated from interviews with 16 patients
being treated in NHS Trusts in England. The sample in-
clusion criteria were that the patients were aged 18 years
or above and being treated, managed and cared for in
the UK. All patients were undergoing regular reference
treatment i.e. chelation and transfusion dependency. The
exclusion criterion for the study was difficulty with the
command of the English language as the questionnaire
was developed in the English (UK) language.
Interviews were conducted at the convenience of the
patients at their treatment centre.
Patients were identified and recruited by clinical Red
Cell Haematology nurse specialists (CNSs) to represent as
much of the diversity of the illness as possible. Patients
were identified using Electronic medical records (EMRs)
along with the CNSs’ own knowledge of the patients. An
interview schedule served as a guide for each interview to
ensure consistency of questioning. The interview ques-
tions were derived from a comprehensive review of the lit-
erature, multidisciplinary expert opinion, (two health
research Psychologists, a CNS (Rec Cell Haematology)
and two Consultant Haematologists), and the ideas of a
small group of patient ambassadors being cared for in one
NHS Trust. Questions included, ‘What impact does Thal-
assaemia have on: family life, friends/social activities/hob-
bies, work/professional relationships, education, day to day
life, body image, future plans’? After each interview, each
interviewee was asked if there was anything more that
they wanted to add to the discussion to ensure that all
relevant questions/issues were addressed.
The interviews were transcribed verbatim and their
content thematically analysed by the two health research
Psychologists individually and iteratively; accord on the
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themes was achieved after discussion amongst these ex-
perts. Thematic analysis is an effective and explicit ap-
proach for identifying, analysing and reporting themes
when research is addressing an exploratory question. It
is a flexible yet clearly defined approach that provides an
accessible method of analysis to a novice qualitative re-
searcher and supports a realist theoretical approach [18].
Pre-testing
Patients helped to shape the design of the ThALI, its
statements and subscales.
The preliminary questionnaire including its instruc-
tions, item-stems, items and response options, was
reviewed for content, wording and clinical appropriate-
ness by patients and clinicians [7].
There is no optimum number of participants that is
needed for pre-testing an instrument [19] so 10 adult
patients with βTM were invited to take part in the pre-
testing. This group of patients included 5 patients who
were interviewed in stage 1 who were receptive to help
with the project after being involved at the interview
stage, as well as a small, independent, clinical group of 5
heterogeneous patients with βTM from one of the 5 par-
ticipating Trusts [7]. Trust clinicians working within the
thalassaemia multidisciplinary team were also invited to
review the questionnaire individually for clinical appro-
priateness. This ensured content validity. Their individ-
ual reviews were collated by the study researcher.
Patients were asked to complete the questionnaire in
the presence of the study investigator and to review it by
identifying items, item stems and instructions that were
unclear, ambiguous, irrelevant, misleading and/or offen-
sive and to make suggestions for adjustments to the
questionnaire [7]. One-to-one, informal discussions
using the ‘think aloud’ approach were ‘conducted’ with
each patient [7]. This method is used to gather data for
the design and development of ‘products’ in psychology
and the social sciences and avoids interpretation by the
‘subject’ assuming that simple verbalisation in the dis-
cussion process should considered objective data [7, 20].
In this stage, the questionnaire was administered by
postal survey to a community sample of 381 adult βTM
patients recruited from the UK Thalassaemia charity [7].
Stage 2 of 2: item reduction
Exploratory Factor Analysis was adopted for item reduc-
tion to develop the final version of the ThALI using vari-
max rotation. The overarching goal of EFA is to identify
the underlying relationships/structure between measured
variables. It is generally considered to be more of a
theory-generating than a theory-testing procedure [17].
Although EFA is not based on theoretical criteria do-
mains of interest/importance can be identified by re-
searchers even though there was no statistical basis and
associations may be examined between variables using
methods of statistics therefore is suited for EFA as per
psychometric theory [21]. This was the case in this re-
search. In using EFA, researchers can identify a sample
that exhibits a spread in scores. Exploratory factor analysis
(EFA) was used to identify a group of items that appeared
to measure the domains of general physical health (GPH),
psychological health and personal beliefs – coping (C),
psychological health and personal beliefs – body image,
appearance and confidence (BIAC), social relationships
(SR), and autonomy (A). Although the THALI measure is
multidimensional each subscale is intended to be unidi-
mensional. Unidimensional subscales were created using
maximum likelihood factor analysis.
Ninety-one patients (male, 47%; female, 53%; age range
19-68; M = 33.74; SD = 9.63) completed the questionnaires
at this stage of the study. Table 1 shows more detailed char-
acteristics of this patient sample. The patients involved in
the study were representative of the cross-cultural diversity
of persons with the illness in question so that the ThALI
was sensitive to the needs of this patient group.
The decision to have 7 items per sub-scale prior to ex-
ploratory factor analysis (EFA) was made to optimise
consistency and to ensure an appropriate balance be-
tween generating a short scale (for quick completion
and scoring) and having enough items to generate ad-
equate score variability [7]. The development of scales
based on pre-determined number of items to retain has
been used frequently to facilitate scale comparisons e.g.
General Health Questionnaire-28 (GHQ-28) [7, 23].
Although the ThALI measure aimed to be multidi-
mensional, we hypothesised that the sub-domains/sub-
scales would be uni-dimensional. Data was tested using
maximum likelihood factor analysis which has much
better statistical properties than other methods of esti-
mation in factor analyses such as Principle Component
Analysis (PCA) [7, 21].
Results
Stage 1 of 2: item generation and pre-testing
Item generation
A total of 158 health impact phrases/statements were
extracted from the interviews [7]. Statements with a high
degree of overlap (commonality and similarity) were
rejected. Statements were chosen to avoid idiosyncratic
and highly specific responses [7]. Statements regarding
positive coping with βTM were excluded since the focus
was on the negative impact of βTM on patients’ lives [7].
A 61-item questionnaire was fashioned.
All the phrases/statements, which became the tool’s
items, referred to the present and were written corres-
pondingly in the first-person using words deemed familiar
to all adults [7]. All the items were written in one direc-
tion for clarity and none presented in reverse format [7].
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All items were to be answered with the preceding 4 weeks
in mind; this timeframe relates to the treatment of this ill-
ness i.e. frequency of blood transfusions [7].
Upon examination of the content and wording of the
items, 2 distinct question stems were deemed appropri-
ate [7]. Most of the items (n=33) were best represented
by the stem, ‘In the past four weeks, I have… ’[7]. Fifteen
items describe general physical symptoms; 18 items de-
scribe psychological and personal thinking [7]. Eight
items describe body image and are best represented by
the stem, ‘In the past four weeks, it has bothered me
that… [7]. The remaining items (n=20) are statements
relating to social relationships and autonomy and were
best represented by the stem, ‘In the past four weeks…
’[7]. The most widely-used psychometric response scale
for surveys is the 5-point Likert scale [24] and was
deemed the most appropriate in this case [7]. Responses
are anchored from ‘1’ (not at all), to ‘5’ (extremely) [7].
The higher the score, the poorer the QoL.
Inductive themes, which became the tool’s sub-scales,
emerged from the verbatim transcribed interviews of the
patients and were captured using key words [7]. The 5
broad emergent themes were: general physical health
(GPH), coping (C), body image, appearance and confi-
dence (BIAC), social relationships (SR) and autonomy
(A), which endorses the multidimensionality of QoL [7,
14]. The interviewees were shown the themes and the
organisation of the statements in the questionnaire
(Table 2); all were satisfied with the outcome of the ana-
lyses. The broad themes encompassed appropriate
groups of items. The five sub-scales encompassed the
three distinct dimensions of subjective health status, the
biopsychosocial impact of illness, in this case of βTM.
The experts - the two health research Psychologists, the
CNS (REC Cell Haematology) and the two Consultant
Table 1 Community sample characteristics
Variable Value in %
or n
Gender
Female 47%
Male 53%
Age
Mean (SD) 33.74 (9.63)
Range 19–68
Ethnicity
Greek Cypriot 36%
Indian 25%
Greek 10%
Middle Eastern 10%
Chinese 8%
White British 5%
Turkish Cypriot 3%
Pakistani 3%
Educational status
No qualifications 7%
G.C.S.E. or equivalent i.e. school leaver qualification(s) 34%
University entry or equivalent qualification(s) 13%
Graduate degree or equivalent qualification(s) 38%
Higher degree or equivalent qualification(s) i.e.
postgraduate or PhD
8%
Employment status
Employed 69%
Self-employed 3%
Unemployed 10%
Other (student/housewife) 18%
Marital status
Single 58%
Married 35%
Living together as married 7%
Dependents
Mean (SD) 0.47 (0.99)
(Range) (0–5)
Treatment type
‘Pump’ 32%
Oral chelator drug 34%
Combination 34%
Illness complication(s)
Osteoporosis/Osteoarthritisa 28%
Diabetes 22%
Cardiac problems 10%
Hypothyroidismb 8%
Impaired glucose tolerance 6%
Table 1 Community sample characteristics (Continued)
Variable Value in %
or n
Asthma 4%
Other (not stated) 4%
Hepatitis Cc 4%
Insensitivity to pain 4%
Eczema 4%
Coeliac diseased 2%
Hormonal Imbalance 2%
aLoss of bone tissue causing the bone to become brittle and fracture easily/a
common joint disease characterized by degeneration of the cartilage that lines
joints or by formation of an outgrowth of bone at the boundary of a joint
(osteophyte), leading to pain, stiffness and occasionally loss of function [22].
bThe underproduction of thyroid hormones by an underactive thyroid gland
[22]. cInfection often transmitted through sharing needles and/or blood
transfusions; can progress to cirrhosis (long term damage to liver cells) and/or
hepatoma (a type of liver cancer) [22]dThe lining of the small intestine gets
damaged due to hypersentivity to gluten (protein found in wheat, rye and
other cereals) [22]
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Haematologists - agreed that the five sub-scales fell nat-
urally into the 3 dimension of health status.
Table 2 shows the facets incorporated within the five
themes and the definition of the sub-scale category.
Pre-testing
All the opinions of the patients were considered and were
very positive. All 10 patients stated that the instructions were
easy to follow; five found it easy to complete [7]. Two pa-
tients mentioned that the layout was good; two stated that it
had good readability and three found it “straightforward and
precise” [7]. Two patients commented that the questionnaire
was “all-encompassing” and three stated that the question-
naire was much needed [7]. Seven patients remarked that
the content was fine and six found it interesting [7]. All the
patients commented that the item ‘I have been angry and
frustrated’, could be separated out into two items and that
the word ‘aggressive’ in one of the items could be replaced
with the word hostile so not to offend and/or upset patients.
Patients did not suggest additional concepts or identify con-
cepts not relevant and/or important to their experience.
The clinicians added one item based upon the physical
clinical features of the illness; this was ‘My arms are long’.
No items were eliminated. After pre-testing, the prelim-
inary 61 item questionnaire was expanded to 63 items.
Data analysis
Stage 2 of 2: item reduction Seven items were chosen
per sub-scale with items loading on the factor > 0.40 as
per ‘rule of thumb’ [7, 25] to ensure the identification of
moderate to very strong relationships. Given the import-
ance of the issues/concerns stated by patients, the authors
sought to ensure that the strongest items were identified
within a short tool that was fit for purpose. The authors are
aware that classes of relationships can be arbitrary. Know-
ingly they resolved not to identify weak and loose relation-
ships which could have theoretically excluded items that
didn’t ‘fit’ into sub-scales. The factor loadings for the items
that were retained were all adequate, ranging from 0.66–
0.86 for GPH, 0.80 – 0.88 for C, 0.53 – 0.78 for BIAC, 0.41
– 0.86 for SR and 0.73 – 0.88 for A [7]. Table 3 shows the
factors (by sub-scales and items) by size of loadings.
Item discriminant validity was assessed by correlating
each item with the total sub-scale across all sub-scales.
Within all the sub-scales, most correlations were signifi-
cant at the 0.01 level (two tailed) [7]. The scores within
this sample were widespread. Although the sample size
was small, 60% of the correlations were strong (>0.75).
As the UK adult thalassaemia population is small [26]
this sample size was satisfactory [7, 27].
The descriptive statistics and response data of the 5
sub-scales of the ThALI are reported in Tables 4 and 5.
Table 4 essentially shows some descriptive scores for the
items within sub-scale. Table 5 shows further compe-
tences of the sub-scales.
Each of the sub-scales generated scores between 13.42
and 19.13 out of a possible 35 [7]. The standard devi-
ation of the mean scores per sub-scale are below the
sub-scale midpoint (21.00) [7].
Table 2 Themes and Health Impact Statement Organisation
Scale category Facets incorporated within domains (themes emerged
during the extraction process)
Definition of scale category
General physical health (GPH) - Overall QoL and general health Self-evaluation of personal physical health status
- Energy, fatigue/tiredness
- Pain and discomfort
- Sleep
Autonomy (A) - Mobility Self-evaluation of feelings of dependency and control in
usual physical role activities
- Achievements/normality
- Education and work
- Activities of daily living
Coping (C) - Feelings/emotions Self-evaluation of psychological upset and/or well-being in
relation to purpose drive coping.
- Thinking and
Concentration
- Planning ahead
Body image, appearance and
confidence (BIAC)
- Bodily image Self-evaluation and feelings about physical self
- Self-esteem and confidence
Social relationships (SR) - Relationships and support network Self-evaluation of limitations in social activities from
physical and emotional difficulties.
- Leisure/social activities
- Stigma
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The analysis of the internal consistency of the sub-
scales was evaluated with Cronbach’s α; all the estimates
were high (0.83-0.94; GPH 0.90, C 0.84, BIAC, 0.83, SR
0.83, A 0.94) [7].
Table 6 shows the (Pearson) correlations between the
5 sub-scales. All the correlations were positive and sig-
nificant seemingly due to the sub-scale measurement of
a broader global outcome of QoL [7].
Discussion
The developed ThALI is a sound disease-specific health
outcome measure for the chelation and transfusion
dependent βTM adult population. As it has been devel-
oped in collaboration with service users, it presents the
issues and/or concerns of this patient group. The ThALI
supports the 3 distinct dimensions of subjective health
in βTM patients and shows that accommodation to this
chronic illness is indeed multi-dimensional with dynam-
ically interacting facets [7]. The data are promising; per-
ceived quality of life could possibly play a significant role
in predicting adjustment to and/or coping with βTM [7],
however, such extrapolations need to await empirical
verification. The present study provides an adequate
starting point.
Quality of life (QoL) consists of subjective and bio-
logical factors that relates to the personal experiences of
chronically ill service users [7, 28]. As people with other
chronic medical conditions have a higher risk of devel-
oping mental health problems [7, 29] it would make
sense that healthcare professionals listen to the lived ex-
periences of chronically ill service users to benefit future
suffering despite physical health problems. Doctors may
be well equipped for the biomedical aspects of care but
not for the challenges of understanding the psycho-
logical, social, and cultural dimensions of illness and
health [30]. This is where the patient/service user voice
is needed and why their involvement in the development
of a tool to assess the impact of illness on their life is of
paramount importance.
Scoring and interpreting the scores of the ThALI
Completing the ThALI takes approximately 5 minutes.
Scores can be obtained for the total scale and/or its sub-
scales. The authors suggest a simplistic preliminary
method of interpreting scores. The ThALI categorises
scores are 35-69 as limited/few problems, 70-104 as few
problems, 105-139 as moderate problems and 140-175
as significant problems [7]. As previously stated, the
higher the score, the poorer the QoL.
Limitations
Whilst the ThALI was indeed developed in collaboration
with service users and indeed presents the issues and/or
concerns of this patient group the decision to exclude
‘weak’ items in the tool could have resulted in the exclu-
sion of when reducing items from the bigger tool to the
final 35 item tool. The ThALI will endeavour to undergo
a national authentication with a clinical sample of chela-
tion and transfusion dependent adult patients with βTM
who are being cared for at Centres of Excellence in NHS
Trusts in England. The ThALI will be administered to this
group of service users along with other measures of sub-
jective biopsychosocial functioning. The results will allow
further assessment of the reliability and validity of the
questionnaire. At this stage, interested adult patients will
be recruited and trained by REC Cell Haematology CNSs
working at the Centres to administer the questionnaires
to their fellow patients. In this way, the implementation of
the Therapeutic Engagement Questionnaire (TEQ) [31]
within this patient group may be facilitated; the service
user researchers can feedback any practicalities in its ad-
ministration and any patient issues/concerns not already
accounted for (if any) within the clinical environments
with those with lived experience.
Table 3 Order (by size of loadings) in which ThALI statements contribute to Factors (sub-scales)
Factor 1
(GPH)
Factor 2
(C)
Factor 3
(BIAC)
Factor 4
(SR)
Factor 5
(A)
Item Loading Item Loading Item Loading Item Loading Item Loading
Tired 0.86 Frust. 0.88 Shortened body 0.78 Rejected 0.86 Mobility 0.88
Run
down
0.85 Angry 0.84 Short in height 0.77 Penalised 0.79 Lifting 0.87
Energy 0.78 Irritable 0.82 Look younger than peers 0.66 Social life affected 0.79 Walking 0.86
Needed
Rest
0.74 Emotional 0.81 Conscious of being different
to others
0.66 Unable to form
relationships
0.56 Most things
difficult (gen)
0.82
Stamina 0.73 Anxious 0.81 Pale complexion 0.58 Limited leisure
activities
0.53 Bending 0.82
Aches/
pains
0.67 Stressed 0.80 Inferior 0.58 Family life restrictions 0.51 Struggle with life
routine
0.77
Dizzy 0.66 Worried 0.80 Self-confidence 0.53 Short with family 0.41 Doing chores 0.73
General physical health (GPH); Coping (C); Body image, appearance and confidence (BIAC); Social relationships (SR); Autonomy (A)
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From a statistical viewpoint, correlation coefficients
tend to be less reliable when estimated from small sam-
ples. However, although the sample size was small 60%
of the correlations were strong (> 0.75), all were reliable
and the themes few. The UK adult thalassaemia popula-
tion is small [4] therefore this sample size was sufficient
[27]. Studies of this patient group are generally small,
volunteer or self-selected groups thus restricting the
generalisation of the study findings [32, 33]. In addition,
the disadvantage of using the charity database to define
the sampling frame in stage 2 is that the ‘psychological’
representativeness of people who join charitable groups
is unknown. Further sampling would be essential to esti-
mate the generalisability of the measure for use with
people with thalassaemia in general.
With regards to the data analyses at the item reduc-
tion stage, we acknowledge that the factor analysis did
not control for the different item stems, hence question
structure. Although content validity was high, this was
not accounted for. Although the ThALI was developed
in collaboration with patients more direct involvement
by patients could always occur in studies such as this.
Strengths
The strength of this project derives from the collabor-
ation with service users at both stages of the ThALI’s de-
velopment. Patients involved in the study represented
the diversity of persons with thalassamia so the ThALI is
sensitive to the needs of this patient group. The involve-
ment of patients in research enables them to develop a
sense of empowerment and provides opportunity to
share and allow others to benefit from their unique ex-
perience [34].
Patient experience narratives from the interviews in
stage 1 led to the development of a metric that is clinic-
ally appropriate to those who access health and social
care services for their care and treatment. These patients
provided a realistic and ‘lived’ representation of living
with βTM [22, 35] and sound feedback was given at the
pre-testing stage to revise the tool. Patient input contrib-
uted considerably to the content and design of the
ThALI which determined the development of a ‘patient-
friendly’ measure.
Conclusions
The development of the ThALI in an English adult che-
lation and transfusion dependent βTM patient popula-
tion was accomplished in collaboration with patients
and is available for use by healthcare professionals and
researchers to measure the biopsychosocial impact of
βTM. With the aid of service user researchers, further
research should aim to use and test the ThALI in other
NHS Trusts in England and in countries where preva-
lence of βTM is commonplace. The THALI was devel-
oped for an English-speaking population however due to
the ethnic demographic status of βTM patients, the au-
thors support that the tool be translated into other
languages.
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Table 4 THALI descriptive statistics
Psychometric Properties GPH C BIAC SR A
Item Mean Score Range 1.46–
2.78
1.73–
2.38
1.34–
1.72
1.31–
2.10
0.77–
2.20
Item SD Range 2.61–
3.22
2.55–
3.12
2.15–
3.06
2.08–
2.65
2.62–
5.51
Item Skewness Range −3.95 –
− 2.79
−3.47 –
− 3.08
−3.32 –
− 2.63
−3.41 –
− 2.90
−3.30 –
− 1.02
Item correlation with
Hypothesised Scale
Range
r =
0.72–
0.88
r =
0.83–
0.91
r =
0.63–
0.77
r =
0.62–
0.83
r =
0.79–
0.90
General physical health (GPH); Coping (C); Body image, appearance and
confidence (BIAC); Social relationships (SR); Autonomy (A)
Table 5 THALI Acceptability
Psychometric Properties GPH C B SR A
Total Possible Score Range
per item
7–35 7–35 7–35 7–35 7–35
Total Observed Score
Range
9–34 7–34 7–32 7–31 7–35
Mean Observed Score (SD) 19.13 17.45 13.42 13.93 16.14
Floor/Ceiling Effect No No Floor
(19.27%)
Floor
(15.48%)
No
Skewness 0.39 0.50 0.98 0.88 0.76
General physical health (GPH); Coping (C); Body image, appearance and
confidence (BIAC); Social relationships (SR); Autonomy (A)
Table 6 Subscale Correlation Matrix
GPH C BIAC SR A
GPH 1.00 0.58(**) 0.36(**) 0.55(**) 0.61(**)
C 0.58(**) 1.00 0.49(**) 0.54(**) 0.61(**)
BIAC 0.36(**) 0.49(**) 1.00 0.60(**) 0.52(**)
SR 0.55(**) 0.54(**) 0.60(**) 1.00 0.78(**)
A 0.61(**) 0.61(**) 0.52(**) 0.78(**) 1.00
General physical health (GPH); Coping (C); Body image, appearance and
confidence (BIAC); Social relationships (SR); Autonomy (A)
** Correlation is significant at the 0.01 level (2-tailed); N = 91 for all correlations
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